Please assess the completion status of the following clinical trial:

Trial Title: VIR-7831 for the Early Treatment of COVID-19 in Outpatients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be aged 18 years or older AND at high risk of progression of COVID-19 or ≥ 55 years old~* Participants must have a positive SARS-CoV-2 test result and oxygen saturation ≥94% on room air and have COVID-19 symptoms and be less than or equal to 5 days from onset of symptoms~Exclusion Criteria:~* Currently hospitalized or judged by the investigator as likely to require hospitalization in the next 24 hours~* Symptoms consistent with severe COVID-19~* Participants who, in the judgement of the investigator are likely to die in the next 7 days~* Severely immunocompromised participants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VIR-7831 (Sotrovimab) (Type: EXPERIMENTAL): Participants received 500 mg sotrovimab administered intravenously (IV)
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered intravenously (IV)

Based on this trial design, predict the completion outcome and termination type (if applicable).